Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
372.25
+12.32 (3.42%)
At close: Jun 26, 2026, 4:00 PM EDT
368.00
-4.25 (-1.14%)
After-hours: Jun 26, 2026, 7:49 PM EDT
Krystal Biotech Employees
Krystal Biotech had 295 employees as of December 31, 2025. The number of employees increased by 20 or 7.27% compared to the previous year.
Employees
295
Change (1Y)
20
Growth (1Y)
7.27%
Revenue / Employee
$1,414,590
Profits / Employee
$762,814
Market Cap
10.97B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 1,220 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Summit Therapeutics | 265 |
KRYS News
- 8 days ago - Krystal Biotech price target raised to $403 from $306 at TD Cowen - TheFly
- 10 days ago - Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright - TheFly
- 5 weeks ago - Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - GlobeNewsWire
- 5 weeks ago - Krystal Biotech Slides: Corporate presentation - Filings
- 5 weeks ago - Krystal Biotech announces UK MHRA approval of Vyjuvek - TheFly
- 5 weeks ago - Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 6 weeks ago - Krystal Biotech Transcript: AGM 2026 - Transcripts
- 6 weeks ago - U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa - TheFly